Clinical Trials on PIK3CA Mutation in Netherlands

Total 61 results

Novartis Pharmaceuticals

Recruiting

Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (EPIK-P2)

PIK3CA-related Overgrowth Spectrum (PROS)

United States, Canada, Spain, Switzerland, France, United Kingdom, Germany, Italy, China, Hong Kong, Netherlands, Norway
Sint Maartenskliniek

Completed

Effect of Sports-oriented Rehabilitation on Mobility and Daily Activity in People With a Lower-limb Amputation

Amputation | Lower Limb Amputation

Netherlands
Sint Maartenskliniek

Completed

Reverse Innovation in Western Health Care: the ReMotion Prosthetic Knee.

Lower Limb Amputation Above Knee (Injury) | Lower Limb Amputation Knee

Netherlands
Erasmus Medical Center

Recruiting

Bilateral Prophylactic Mastectomy; Should we Preserve the Pectoral Fascia? (PROFAS)

Seroma | BRCA1/2 Mutation | Bilateral Prophylactic Mastectomy | Pectoral Fascia

Netherlands
University Medical Center Nijmegen

Recruiting

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention (TUBA-WISP-II)

Ovarian Cancer | BRCA1 Gene Mutation | BRCA2 Gene Mutation | RAD51C Gene Mutation | RAD51D Gene Mutation | BRIP1 Gene Mutation

Netherlands, United States, Belgium, Norway, Poland, Italy, Australia, Mexico, Brazil, Sweden, Uruguay
The Netherlands Cancer Institute
Radboud University Medical Center; Erasmus Medical Center; Dutch Cancer Society

Unknown

Health After eaRly Menopause Due to Oophorectomy (HARMOny)

Cardiovascular Diseases | Quality of Life | Cognitive Decline | BRCA1 Mutation | BRCA2 Mutation | Bone Mineral Density | Surgical Menopause | Menopause Surgical

Netherlands
Boehringer Ingelheim

Active, not recruiting

A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)

Solid Tumors, KRAS Mutation; SOS1

United States, Netherlands, Germany
Bayer

Completed

A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants

Healthy Volunteers | Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

Netherlands
Radboud University Medical Center

Unknown

Patient Empowerment by Group Medical Consultations (GMC)

Breast Cancer | BRCA Mutation

Netherlands
University Medical Center Groningen
ZonMw: The Netherlands Organisation for Health Research and Development

Completed

Economic Evaluation of Lower Limb Prostheses for Persons With a Knee-disarticulation or Transfemoral Amputation

Amputation | Prosthesis | Prosthesis User

Netherlands
M.p. van den Berg, MD, PhD, professor in Cardiology
University Medical Center Groningen; ZonMw: The Netherlands Organisation for... and other collaborators

Completed

PHOspholamban RElated CArdiomyopathy STudy - Intervention (i-PHORECAST)

Phospholamban R14del Mutation-related Cardiomyopathy

Netherlands
Leiden University Medical Center
University Medical Center Groningen; Erasmus Medical Center

Recruiting

Functional Analysis of BRCAness (FAB)

BRCA1 Mutation | BRCA2 Mutation | Homologous Recombination Deficiency | Ovarian Neoplasm Epithelial

Netherlands
Nanne Kleefstra

Completed

Effects of Writing Down the Request for Help on Patient Satisfaction in General Practices

Patient Satisfaction | Doctor Satisfaction | Duration of Consultation

Netherlands
Novartis Pharmaceuticals

Completed

A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene

Estrogen Receptor Positive Breast Cancer | Advanced Solid Tumors With an Alteration of the PIK3CA Gene

United States, Netherlands, Spain, Germany, United Kingdom
The Netherlands Cancer Institute
Lustgarten Foundation

Recruiting

Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers (SHERPA)

Colorectal Cancer | Pancreatic Cancer | Non-small Cell Lung Cancer | KRAS Mutation-Related Tumors

Netherlands
University Medical Center Groningen
ZonMw: The Netherlands Organisation for Health Research and Development

Recruiting

Effectiveness and Cost-effectiveness of Lower Limb Prostheses

Amputation | Prosthesis | Prosthesis User

Netherlands
Amsterdam UMC, location VUmc

Unknown

Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients

NSCLC | EGFR-mutation | HER2-expression

Netherlands
Leiden University Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development

Unknown

The Efficacy of a Cognitive-Behavioural Intervention in Deliberate Self-Harm Patients

Self-Injurious Behavior

Netherlands
ETOP IBCSG Partners Foundation
AstraZeneca

Active, not recruiting

Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO) (STEREO)

NSCLC Stage IV | EGFR Gene Mutation

Singapore, Sweden, Korea, Republic of, Spain, Switzerland, Netherlands, Italy, Poland
University Medical Center Groningen

Active, not recruiting

Nutrition in People With a Lower Limb Amputation

Nutrition Disorders | Amputation | Diet, Food, and Nutrition

Netherlands
Leiden University Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development; University...

Unknown

The (Cost-) Effectiveness of Mindfulness-training and Cognitive Behavioural Therapy in Adolescents and Young Adults With Deliberate Self Harm (DSH)

Self-Injurious Behavior

Netherlands
University Medical Center Nijmegen

Active, not recruiting

Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation Carriers (TUBA)

Ovarian Cancer | BRCA1 Gene Mutation | BRCA2 Gene Mutation

Netherlands
Radboud University Medical Center
A-T Children's Project; Twan foundation (https://twanfoundation.nl)

Completed

Effects of Vitamin B3 in Patients With Ataxia Telangiectasia

Ataxia Telangiectasia | ATM Gene Mutation

Netherlands
Khondrion BV
Julius Clinical; ProPharma Group; Europees Fonds voor Regionale Ontwikkeling... and other collaborators

Active, not recruiting

The KHENERGYC Study

Mitochondrial Diseases | MELAS | Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation | Subacute Necrotizing Encephalomyelopathy

Netherlands
Novartis Pharmaceuticals

Active, not recruiting

A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

Advanced Malignancies That Harbor IDHR132 Mutations

Belgium, Germany, Spain, Canada, Australia, United States, Netherlands, Singapore
Blueprint Medicines Corporation

Active, not recruiting

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Neoplasms, Nerve Tissue | EGF-R Positive Non-Small Cell Lung... and other conditions

United States, Canada, Taiwan, Korea, Republic of, Singapore, Japan, United Kingdom, France, Netherlands, Spain
AstraZeneca

Completed

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation

United States, Canada, Netherlands
Bayer

Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

Hong Kong, United States, Taiwan, Spain, Belgium, China, Japan, France, Korea, Republic of, Singapore, Poland, Israel, Italy, Netherlands, Portugal, Brazil
SwanBio Therapeutics, Inc.

Active, not recruiting

Study of Disease Progression in Adults With Inherited Forms of Spastic Paraplegia (CYGNET)

AMN | AMN Gene Mutation | X-ALD

United States, Netherlands, Germany
ArriVent BioPharma, Inc.

Recruiting

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | HER2 Exon 20 Mutations | EGFR Exon 20 Mutations | EGFR Uncommon Mutations, Including G719X and S768I

United States, Australia, Spain, United Kingdom, France, Italy, China, Korea, Republic of, Canada, Japan, Netherlands
SwanBio Therapeutics, Inc.

Recruiting

A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN) (PROPEL)

AMN | AMN Gene Mutation | X-ALD

Netherlands, United States
Academisch Medisch Centrum - Universiteit van Amsterdam...
ZonMw: The Netherlands Organisation for Health Research and Development

Recruiting

Does Increasing Oxygen Nurture Your Symptomatic Ischemic Ulcer Sufficiently? (DIONYSIUS)

Amputation | Peripheral Vascular Disease | Diabetic Foot Ulcer

Netherlands
Amgen

Recruiting

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Advanced Solid Tumors | Kirsten Rat Sarcoma (KRAS) pG12C Mutation

United States, Italy, Taiwan, Spain, United Kingdom, Australia, Austria, Germany, Belgium, Japan, Netherlands, Korea, Republic of, Canada
University Medical Center Groningen
Radboud University Medical Center; Maastricht University Medical Center; Erasmus... and other collaborators

Recruiting

Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels (ADAPT ALEC)

Carcinoma, Non-Small-Cell Lung | Lung Cancer | Drug Monitoring | Anaplastic Lymphoma Kinase Gene Mutation | Anaplastic Lymphoma Kinase Gene Translocation

Netherlands, France
Novartis Pharmaceuticals

Completed

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3 | Squamous Lung Cancer With FGFR1 Amplification | Bladder Cancer With FGFR3 Mutation or Fusion | Advanced Solid Tumors With FGFR1 Amplication | Advanced Solid Tumors With FGFR2 Amplication | Advanced Solid Tumors With FGFR3 Mutation

France, Spain, Taiwan, Germany, Netherlands, Singapore, United States, Australia, Korea, Republic of, Thailand, Israel, Italy, Turkey, Austria
AstraZeneca

Completed

Europe-Japan Diagnostic Study for EGFR Testing (ASSESS)

EGFR Mutation Status in aNSCLC Patients (Locally Advanced and/or Metastatic Disease) With Adenocarcinoma and Non-adenocarcinoma Histologies.

Italy, Spain, United Kingdom, Sweden, Japan, Netherlands, Germany, France
Relay Therapeutics, Inc.

Active, not recruiting

REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | FGFR2 Gene Mutation | FGFR2 Amplification | FGFR2 Gene Fusion/Rearrangement | FGFR2 Gene Translocation | FGFR2 Gene Activation | Other Solid Tumors, Adult

United States, France, Italy, United Kingdom, Korea, Republic of, Spain, Taiwan, Sweden, Germany, Netherlands, Singapore, Australia, Hong Kong
AstraZeneca

Active, not recruiting

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Cervical Cancer | Ovarian Cancer | Pharmacokinetics | Endometrial Cancer | Pharmacodynamics | Safety and Tolerability | Advanced Solid Malignancy | Tumour Response | Advanced or Metastatic Breast Cancer | PIK3CA | AKT1 | PTEN | ER Positive | HER2 Positive

United States, Italy, Canada, France, Japan, United Kingdom, Spain, Netherlands, Denmark, Singapore
Prelude Therapeutics

Recruiting

PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation

Advanced Solid Tumor | Metastatic Solid Tumor | Non-small Cell Lung Cancers | SMARCA4 Gene Mutation

United States, France, Spain, Singapore, Netherlands
Kura Oncology, Inc.

Active, not recruiting

Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy (AIM-HN/SEQ-HN)

HNSCC | HRAS Gene Mutation

United States, Belgium, Spain, United Kingdom, Taiwan, Denmark, Korea, Republic of, Netherlands, Thailand, Germany, Malaysia, Austria, Italy, Greece, Australia, Norway
Verastem, Inc.
Amgen

Recruiting

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients (RAMP203)

Non Small Cell Lung Cancer | KRAS Activating Mutation

United States, Spain, France, United Kingdom, Netherlands, Belgium
FORUM Pharmaceuticals Inc

Unknown

Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation

Granulin Mutation

Belgium, United States, France, Italy, Netherlands, United Kingdom
Tesaro, Inc.
European Organisation for Research and Treatment of Cancer - EORTC; Breast... and other collaborators

Terminated

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients (BRAVO)

Ovarian Neoplasms | BRCA1 Gene Mutation | BRCA2 Gene Mutation | Neoplasms, Breast | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Carcinoma of Breast

United States, Spain, Belgium, Israel, United Kingdom, Italy, Poland, Canada, Hungary, Netherlands, France, Portugal, Greece, Iceland
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma

c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM

Spain, Switzerland, Germany, United States, Netherlands
Centre Leon Berard

Recruiting

Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING) (TRacKING)

Cancer | Cancer Metastatic | ALK Fusion Protein Expression | FGFR2 Gene Translocation | FGFR3 Gene Translocation | NTRK Family Gene Mutation | Gene Fusion | ROS1 Gene Translocation | NTRK Gene Fusion Overexpression | ATIC-ALK Fusion Protein Expression | BCR-FGFR1 Fusion Protein Expression | COL1A1-PDGFB Fusion... and other conditions

France, Denmark, Netherlands, Austria, Germany, Italy, United Kingdom, Czechia, Poland, Slovenia, Spain
Pfizer

Terminated

A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation (REALM-DCM)

Dilated Cardiomyopathy | Lamin A/C Gene Mutation

United States, Spain, Canada, Belgium, Italy, Argentina, Mexico, Netherlands, Norway, United Kingdom
Stealth BioTherapeutics Inc.

Active, not recruiting

Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD) (NuPower)

Mitochondrial Diseases | Mitochondrial Myopathies | Mitochondrial Complex I Deficiency | Mitochondrial Pathology | Mitochondrial DNA Depletion | Mitochondrial DNA Mutation | Mitochondrial DNA Deletion | Mitochondrial Metabolism Defect

Spain, United States, Italy, Netherlands, Australia, Germany, Hungary, New Zealand, Norway, United Kingdom
Cullinan Therapeutics Inc.

Recruiting

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer (REZILIENT1)

Non Small Cell Lung Cancer | EGFR Exon 20 Mutation

United States, Taiwan, Spain, Korea, Republic of, Japan, Singapore, Italy, Netherlands, Hong Kong
Khondrion BV
Julius Clinical; ProPharma Group; Certara

Completed

The KHENEREXT Study

Mitochondrial Diseases | Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation | Maternally Inherited Diabetes and Deafness (MIDD) | Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke Like Episodes (MELAS) | Chronic Progressive External Ophthalmoplegia (CPEO)

Netherlands, Denmark, United Kingdom, Germany
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation

Spain, Italy, Austria, Netherlands, United Kingdom, Germany, Thailand, France, Belgium, China, Argentina, Greece, Turkey, Malaysia, Portugal, Hungary, Brazil, United States, India

Clinical Trials on PIK3CA Mutation in Netherlands

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations